Alexion Pharmaceuticals Inc. (NASDAQ:ALXN)‘s stock had its “neutral” rating reiterated by stock analysts at Wedbush in a note issued to investors on Thursday. They presently have a $135.00 price target on the biopharmaceutical company’s stock. Wedbush’s target price points to a potential upside of 6.17% from the company’s current price.

A number of other brokerages have also recently commented on ALXN. Vetr raised shares of Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating and set a $107.00 price target on the stock in a research report on Thursday, September 29th. Goldman Sachs Group Inc. raised shares of Alexion Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $158.00 price target on the stock in a research report on Friday, October 28th. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $185.00 price target on shares of Alexion Pharmaceuticals in a research report on Tuesday, August 16th. SunTrust Banks Inc. cut their price target on shares of Alexion Pharmaceuticals from $220.00 to $197.00 and set a “buy” rating on the stock in a research report on Wednesday, July 13th. Finally, Credit Suisse Group AG reaffirmed a “buy” rating and set a $165.00 price target on shares of Alexion Pharmaceuticals in a research report on Monday. One analyst has rated the stock with a sell rating, six have given a hold rating and sixteen have issued a buy rating to the company’s stock. Alexion Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $173.36.

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Alexion Pharmaceuticals (NASDAQ:ALXN) opened at 127.16 on Thursday. The stock has a 50 day moving average price of $124.44 and a 200 day moving average price of $131.05. The company has a market cap of $28.51 billion, a PE ratio of 77.54 and a beta of 1.45. Alexion Pharmaceuticals has a one year low of $110.56 and a one year high of $193.45.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, October 27th. The biopharmaceutical company reported $1.23 earnings per share for the quarter, topping the consensus estimate of $1.04 by $0.19. Alexion Pharmaceuticals had a net margin of 12.46% and a return on equity of 10.58%. The company had revenue of $799 million for the quarter, compared to analysts’ expectations of $787.07 million. During the same quarter in the previous year, the firm posted $1.16 earnings per share. Alexion Pharmaceuticals’s revenue for the quarter was up 19.9% on a year-over-year basis. On average, equities analysts anticipate that Alexion Pharmaceuticals will post $4.64 EPS for the current fiscal year.

In other Alexion Pharmaceuticals news, EVP Carsten Thiel sold 4,584 shares of the firm’s stock in a transaction on Friday, October 14th. The shares were sold at an average price of $120.28, for a total value of $551,363.52. Following the completion of the transaction, the executive vice president now directly owns 32,741 shares of the company’s stock, valued at approximately $3,938,087.48. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Edward Miller sold 367 shares of the firm’s stock in a transaction on Friday, September 9th. The shares were sold at an average price of $128.32, for a total transaction of $47,093.44. Following the completion of the transaction, the senior vice president now directly owns 16,519 shares of the company’s stock, valued at $2,119,718.08. The disclosure for this sale can be found here. 4.41% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in ALXN. Suntrust Banks Inc. increased its position in shares of Alexion Pharmaceuticals by 2.0% in the third quarter. Suntrust Banks Inc. now owns 33,087 shares of the biopharmaceutical company’s stock valued at $4,053,000 after buying an additional 659 shares during the last quarter. American International Group Inc. increased its position in shares of Alexion Pharmaceuticals by 0.8% in the third quarter. American International Group Inc. now owns 103,671 shares of the biopharmaceutical company’s stock valued at $12,704,000 after buying an additional 795 shares during the last quarter. BB&T Securities LLC increased its position in shares of Alexion Pharmaceuticals by 39.9% in the third quarter. BB&T Securities LLC now owns 11,934 shares of the biopharmaceutical company’s stock valued at $1,462,000 after buying an additional 3,402 shares during the last quarter. Emerald Acquisition Ltd. increased its position in shares of Alexion Pharmaceuticals by 1.8% in the third quarter. Emerald Acquisition Ltd. now owns 111,421 shares of the biopharmaceutical company’s stock valued at $13,653,000 after buying an additional 1,999 shares during the last quarter. Finally, California State Teachers Retirement System increased its position in shares of Alexion Pharmaceuticals by 0.8% in the third quarter. California State Teachers Retirement System now owns 464,224 shares of the biopharmaceutical company’s stock valued at $56,886,000 after buying an additional 3,900 shares during the last quarter. 96.38% of the stock is owned by hedge funds and other institutional investors.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

5 Day Chart for NASDAQ:ALXN

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.